Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen
Phase 3RecruitingDevelopment Stage
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)
Nov 2, 2021 → Jul 1, 2031
About Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen
Blinatumomab + Low-intensity chemotherapy regimen + SOC chemotherapy regimen is a phase 3 stage product being developed by Amgen for Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL). The current trial status is recruiting. This product is registered under clinical trial identifier NCT04994717. Target conditions include Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL).
What happened to similar drugs?
0 of 4 similar drugs in Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL) were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04994717 | Phase 3 | Recruiting |
Competing Products
18 competing products in Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)